肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌

2020-10-27 Allan MedSci原创

前列腺癌拜耳nmCRPCNubeqa
关注

Nubeqa（darolutamide）已被授权与雄激素剥夺疗法（ADT）一起使用。根据拜耳的说法，这是NICE在这种适应症中推荐的第一种治疗方法。

前列腺癌是英国男性中最常见的癌症，平均每年有48,000多例新病例。在患有非转移性去势抵抗性前列腺癌（nmCRPC）的男性中，约有三分之一在两年内发生转移，这凸显了这类患者的医疗需求。

拜耳的Nubeqa在治疗非转移性去势抵抗性前列腺癌（nmCRPC）方面获得了英国国家健康与护理卓越研究所（NICE）的支持。Nubeqa（darolutamide）已被授权与雄激素剥夺疗法（ADT）一起使用。根据拜耳的说法，这是NICE在这种适应症中推荐的第一种治疗方法。

NICE的推荐是基于ARAMIS III期试验的结果，该试验评估了Nubeqa联合ADT治疗nmCRPC患者的疗效和安全性。在该试验中，Nubeqa联合ADT在无转移生存（MFS）的主要疗效终点方面显示出统计学上的显著改善，中位值为40.4个月，而安慰剂联合ADT仅为18.4个月。总体生存（OS）数据（表明，与安慰剂联合ADT相比，Nubeqa联合ADT组患者的OS得到显著改善，死亡风险降低了31％。

 

原始出处：

http://www.pharmatimes.com/news/bayers_nubeqa_wins_nice_prostate_cancer_backing_1354813

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-29 fusion

    #NICE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-29 ying_wu

    #拜耳#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-28 LUANGUO

    很不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-28 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 水-晶

    继续学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1289092, encodeId=149e12890926e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Oct 29 13:20:32 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895121, encodeId=2b3d89512162, content=很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2170110766, createdName=LUANGUO, createdTime=Wed Oct 28 16:46:11 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040876, encodeId=b74810408e67f, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 28 01:20:32 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894964, encodeId=73168949640b, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Oct 27 23:18:54 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894960, encodeId=abd58949608c, content=继续学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Tue Oct 27 22:55:04 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894955, encodeId=0f6e894955a7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:50:36 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 ms1000002114994444

    学习了

    0

相关资讯

Prostate：去势抵抗性前列腺癌中雄激素受体信号靶向治疗和紫杉醇化疗能够诱导内脏转移

内脏转移(VM)是前列腺癌(PC)的一个重要的不良预后因素，在去势敏感状态下不常见，但在去势抗性产生后经常观察到。然而，VM的部位、出现时间和发生率还未完全阐明。

EBioMedicine：细胞外分泌的烟酰胺磷酸肌转移酶（eNAMPT）在前列腺癌进展中的作用

目前非常需要阻止侵袭性前列腺癌（PCa）的进展。预防侵袭性前列腺癌（PCa）的进展仍然是一个严重的需求。之前的研究表明，细胞外分泌的烟酰胺磷酸肌转移酶（eNAMPT）能够与TLR4结合，是一个具有多功

Eur Urol：有无放疗的雄激素阻断治疗原发性转移前列腺癌患者的生活质量

在雄激素阻断治疗（ADT）的基础上加上局部放疗，能够对低体积转移性前列腺癌（mPCa）患者的生存有益。最近，有研究人员确定了ADT联用前列腺体外放疗（EBRT）对原发性骨mPCa患者的健康相关生活质量

Br J Cancer：LncRNA HOTAIR通过靶向hepaCAM促进前列腺癌的侵袭和转移

前列腺癌（PCa）作为男性中最常见的恶性肿瘤之一，由于早期症状轻微及隐匿性，大多数的病例确诊时已为具有转移性的晚期。尽管目前PCa的治疗取得了许多进展，但多西他赛（docetaxel）并不能有效地改善

Eur Urol：恩杂鲁胺治疗的非转移去势抵抗性前列腺癌男性的前列腺特异性抗原进展研究

前列腺特异性抗原(PSA)的进展没有公认的定义。然而，去势抵抗性前列腺癌（CRPC）患者中PSA的变化可为治疗决策提供信息。最近，有研究人员确定了PCWG2对PSA进展的定义是否足以预测恩杂鲁胺治疗的

Oncogene：去势抵抗性前列腺癌中神经内分泌分化的micromRNA决定因素研究

治疗诱导的神经内分泌前列腺癌（NEPC）是去势抵抗性前列腺癌（CRPC）的一种极具侵袭性的亚型；随着恩杂鲁胺（ENZ）和阿比特龙等高效雄激素受体（AR）通路抑制剂（API）的广泛使用，其发病率越来越高

拓展阅读

JAMA Oncol：基于18基因的尿液检测可准确诊断高级别前列腺癌，可减少约一半的不必要活检

研究确定了高级别前列腺癌特异性过表达的新基因，开发了一种基于尿液的18基因检测（MPS2）。

Mol Cancer：浙江大学郑祥毅/刘犇/罗金旦揭示R环驱动晚期前列腺癌的生长迟缓和多西他赛化疗敏感性增强

该研究表明共转录R环介导的表观遗传调控驱动晚期前列腺癌的生长迟缓和多西他赛化疗敏感性增强。

European Radiology：一种基于磁共振成像的前列腺癌早期诊断筛查方案

现阶段，基于前列腺特异性抗原(PSA)检测的筛查项目降低了死亡率也预防了转移性疾病。然而，这一趋势正在逆转。PCa相关的死亡率在一些国家正在上升，这可能是由于缺乏认识和筛查指南的改变。

World J Urol：前列腺癌根治术后健康和数字健康素养知识对生活质量的影响：一项前瞻性单中心队列研究

研究人员评估了健康素养和电子健康素养对因局部前列腺癌而接受根治性前列腺切除术（RP）男性的生活质量（QoL）的影响。结果发现，自我报告的 HL/e-HL 与 QoL 之间存在正相关关系。

Prostate：中国学者揭示如何在晚期前列腺癌中预测阿比特龙的疗效

研究人员阐明了 KI67 对阿比特龙治疗晚期前列腺癌（PCa）患者疗效方面的预测作用。结果表明，前列腺活检中，KI67 阳性是晚期 PCa 中阿比特龙疗效的有力预测指标。

Eur Urol Focus：转移性前列腺癌患者液体活检样本和肿瘤组织的二代测序可行性如何？

研究人员在前列腺癌患者中，分析了液体活检和肿瘤组织样本进行二代测序（NGS）的可行性和可比性。结果发现，液体活检 NGS 的 BRCA1/2 基因变异检出率更高。